S&P 500   4,285.79 (+0.26%)
DOW   33,624.01 (+0.22%)
QQQ   354.15 (-0.25%)
AAPL   168.92 (-0.89%)
MSFT   310.19 (-0.83%)
META   301.82 (+1.37%)
GOOGL   130.57 (+0.02%)
AMZN   123.63 (-1.87%)
TSLA   239.45 (-0.44%)
NVDA   424.97 (+0.07%)
NIO   8.70 (+2.84%)
BABA   84.71 (-1.72%)
AMD   100.57 (+2.55%)
T   14.90 (+0.20%)
F   12.20 (-1.53%)
MU   65.33 (-4.22%)
CGC   0.78 (-12.61%)
GE   111.51 (+0.56%)
DIS   79.83 (-0.09%)
AMC   7.40 (-2.25%)
PFE   31.84 (-0.81%)
PYPL   57.08 (-0.45%)
NFLX   371.79 (-1.54%)
S&P 500   4,285.79 (+0.26%)
DOW   33,624.01 (+0.22%)
QQQ   354.15 (-0.25%)
AAPL   168.92 (-0.89%)
MSFT   310.19 (-0.83%)
META   301.82 (+1.37%)
GOOGL   130.57 (+0.02%)
AMZN   123.63 (-1.87%)
TSLA   239.45 (-0.44%)
NVDA   424.97 (+0.07%)
NIO   8.70 (+2.84%)
BABA   84.71 (-1.72%)
AMD   100.57 (+2.55%)
T   14.90 (+0.20%)
F   12.20 (-1.53%)
MU   65.33 (-4.22%)
CGC   0.78 (-12.61%)
GE   111.51 (+0.56%)
DIS   79.83 (-0.09%)
AMC   7.40 (-2.25%)
PFE   31.84 (-0.81%)
PYPL   57.08 (-0.45%)
NFLX   371.79 (-1.54%)
S&P 500   4,285.79 (+0.26%)
DOW   33,624.01 (+0.22%)
QQQ   354.15 (-0.25%)
AAPL   168.92 (-0.89%)
MSFT   310.19 (-0.83%)
META   301.82 (+1.37%)
GOOGL   130.57 (+0.02%)
AMZN   123.63 (-1.87%)
TSLA   239.45 (-0.44%)
NVDA   424.97 (+0.07%)
NIO   8.70 (+2.84%)
BABA   84.71 (-1.72%)
AMD   100.57 (+2.55%)
T   14.90 (+0.20%)
F   12.20 (-1.53%)
MU   65.33 (-4.22%)
CGC   0.78 (-12.61%)
GE   111.51 (+0.56%)
DIS   79.83 (-0.09%)
AMC   7.40 (-2.25%)
PFE   31.84 (-0.81%)
PYPL   57.08 (-0.45%)
NFLX   371.79 (-1.54%)
S&P 500   4,285.79 (+0.26%)
DOW   33,624.01 (+0.22%)
QQQ   354.15 (-0.25%)
AAPL   168.92 (-0.89%)
MSFT   310.19 (-0.83%)
META   301.82 (+1.37%)
GOOGL   130.57 (+0.02%)
AMZN   123.63 (-1.87%)
TSLA   239.45 (-0.44%)
NVDA   424.97 (+0.07%)
NIO   8.70 (+2.84%)
BABA   84.71 (-1.72%)
AMD   100.57 (+2.55%)
T   14.90 (+0.20%)
F   12.20 (-1.53%)
MU   65.33 (-4.22%)
CGC   0.78 (-12.61%)
GE   111.51 (+0.56%)
DIS   79.83 (-0.09%)
AMC   7.40 (-2.25%)
PFE   31.84 (-0.81%)
PYPL   57.08 (-0.45%)
NFLX   371.79 (-1.54%)
NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Earnings Date, Estimates & Call Transcripts

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.48
▼
$1.63
50-Day Range
$1.48
▼
$1.98
52-Week Range
$0.82
▼
$3.88
Volume
3.91 million shs
Average Volume
494,777 shs
Market Capitalization
$58.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.91
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

TCRR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TCRR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

TCR2 Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20234($0.94)($0.35)($0.71)
Q2 20234($1.03)($0.36)($0.73)
Q3 20234($1.14)($0.28)($0.72)
Q4 20234($1.18)($0.28)($0.72)
FY 202316($4.29)($1.27)($2.89)

TCR2 Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/11/2023Q1 2023($0.76)($1.03)($0.27)($1.03)--
3/23/2023Q4 2022($0.80)($1.56)($0.76)($1.56)--
11/8/2022Q3 2022($0.83)($0.79)+$0.04($0.79)--
8/8/2022Q2 2022($0.77)($0.82)($0.05)($0.82)--
5/12/2022Q1 2022($0.74)($0.76)($0.02)($0.76)--    
3/22/2022Q4 2021($0.75)($0.72)+$0.03($0.72)--
11/10/2021Q3 2021($0.63)($0.69)($0.06)($0.69)--
8/5/2021Q2 2021($0.60)($0.64)($0.04)($0.64)--
5/13/2021Q1 2021($0.55)($0.58)($0.03)($0.58)--
3/11/2021Q4 2020($0.55)($0.55)-($0.55)--
11/12/2020Q3 2020($0.52)($0.56)($0.04)($0.56)--












TCR2 Therapeutics Earnings - Frequently Asked Questions

How much profit does TCR2 Therapeutics generate each year?

TCR2 Therapeutics (NASDAQ:TCRR) has a recorded net income of -$151.82 million. TCRR has generated -$4.20 earnings per share over the last four quarters.

What is TCR2 Therapeutics's EPS forecast for next year?

TCR2 Therapeutics's earnings are expected to grow from ($2.68) per share to ($0.79) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:TCRR) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -